A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) in children and adolescents with type 1 diabetes (T1D).
Inclusion Criteria:
T1D for at least 6 months at the screening visit.
Have been treated with only one of the following rapid-acting insulin analogs as part of an multiple daily injection regimen for at least the last 90 days prior to the screening visit:
Have been treated with only one of the following basal insulins for at least the last 90 days prior to the screening visit:
Have a HbA1c value ≤ 9.9% at the screening visit.
Exclusion Criteria:
Palo Alto, California 94304, United States
Ostrava-Poruba, 70852, Czechia
Beer Yaakov, 7033001, Israel
Haifa, 3109601, Israel
Saitama-shi, Saitama 330 8777, Japan
Chiyoda-ku, Tokyo 101 8309, Japan
Shinjuku-ku, Tokyo 162-8666, Japan